Junshi Biosciences Chairman Completes RMB100 Million Shareholding Increase

Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) has issued an announcement.

Shanghai Junshi Biosciences has disclosed that its chairman, controlling shareholder and actual controller, Xiong Jun, has completed a planned increase in his holdings of both A shares and H shares of the company. The plan, launched on 12 April 2025, aimed to invest at least RMB100 million in additional shares, with at least RMB50 million in A shares, through exchanges in Shanghai and Hong Kong.

From 12 April 2025 to 31 March 2026, Xiong Jun purchased a total of 3,259,495 A and H shares, representing about 0.32% of the company’s total share capital. The total transaction value reached RMB100.64 million, slightly above the minimum commitment, signaling management’s confidence in the company and resulting in his equity holding crossing the 1% disclosure threshold, a development of note for investors monitoring ownership concentration and governance dynamics.

The most recent analyst rating on (HK:1877) stock is a Hold with a HK$22.50 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.

More about Shanghai Junshi Biosciences Co., Ltd. Class H

Shanghai Junshi Biosciences Co., Ltd. is a China-based biopharmaceutical company listed in both Shanghai and Hong Kong, focused on the research, development and commercialization of innovative therapies. The company operates through A shares on the Shanghai Stock Exchange and H shares on the Stock Exchange of Hong Kong, targeting domestic and international capital markets for its growth and financing needs.

Average Trading Volume: 3,356,361

Technical Sentiment Signal: Sell

Current Market Cap: HK$35.64B

For an in-depth examination of 1877 stock, go to TipRanks’ Overview page.